Episode Details

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss:

- Biogen’s next shot at an Alzheimer’s treatment.

- Why companies can’t “muscle their way” into making new molecules.

- How NVIDIA could change drug development. 

- Moderna’s vaccine strategy

Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX

Host: Deidre Woollard

Guest: Karl Thiel

Producer: Ricky Mulvey

Engineer: Tim Sparks

Learn more about your ad choices. Visit megaphone.fm/adchoices